deltatrials
Terminated PHASE4 INTERVENTIONAL 4-arm NCT03696290

Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis (VitalBE)

A Trial of the Safety, Tolerability and Efficacy of 2 Doses of Cayston (Aztreonam Lysine) Compared to Placebo in Participants With Bronchiectasis

Sponsor: Gilead Sciences

Conditions Bronchiectasis Adult
Interventions Aztreonam lysine Placebo
Updated 17 times since 2018 Last updated: Jan 9, 2026 Started: Oct 19, 2019 Primary completion: Nov 26, 2024 Completion: Mar 4, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Poor recruitment

Other terminated trials from Gilead Sciences

See all terminations from Gilead Sciences

Other Bronchiectasis Adult trials with similar outcome

Browse all Bronchiectasis Adult trials

Listed as NCT03696290, this PHASE4 trial focuses on Bronchiectasis Adult and remains terminated or withdrawn. Sponsored by Gilead Sciences, it has been updated 17 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Aug 2020 · 9 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~May 2023 · 20 months · monthly snapshot~May 2023 – ~Jul 2024 · 14 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Feb 2026 · 16 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

17 versions recorded

  1. Feb 2026 — Present [monthly]

    Terminated PHASE4

    Status: Recruiting → Terminated · Phase: PHASE2 → PHASE4

  2. Oct 2024 — Feb 2026 [monthly]

    Recruiting PHASE2

  3. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  5. May 2023 — Jul 2024 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

▶ Show 12 earlier versions

  1. Sep 2021 — May 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Mar 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  3. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  4. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  5. Nov 2019 — Aug 2020 [monthly]

    Not Yet Recruiting PHASE2

  6. Oct 2019 — Nov 2019 [monthly]

    Not Yet Recruiting PHASE2

  7. Sep 2019 — Oct 2019 [monthly]

    Not Yet Recruiting PHASE2

  8. Jun 2019 — Sep 2019 [monthly]

    Not Yet Recruiting PHASE2

  9. Apr 2019 — Jun 2019 [monthly]

    Not Yet Recruiting PHASE2

  10. Mar 2019 — Apr 2019 [monthly]

    Not Yet Recruiting PHASE2

  11. Jan 2019 — Mar 2019 [monthly]

    Not Yet Recruiting PHASE2

  12. Nov 2018 — Jan 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Gilead Sciences
  • University of Dundee
Data source: University of Dundee

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Cambridge, United Kingdom , Cardiff, United Kingdom , Derby, United Kingdom , Dundee, United Kingdom , East Kilbride, United Kingdom , Harlow, United Kingdom , Liverpool, United Kingdom , London, United Kingdom , Manchester, United Kingdom , Newcastle upon Tyne, United Kingdom and 3 more locations